Autres langues Gain Therapeutics, Inc.

Actions

GANX

US36269B1052

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 01/05/2024			Varia. 5j.	Varia. 1 janv.
2,97 ^USD	+1,37 %		-12,39 %	-9,04 %

24/04	Gain Therapeutics, Inc. annonce des résultats positifs de la dose unique ascendante (SAD) dans le cadre de l'essai clinique de phase 1 de GT-02287	CI
08/04	Gain Therapeutics nomme Gene Mack au poste de directeur financier	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Gain Therapeutics Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease	25/04
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease	24/04
Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287	24/04
Gain Therapeutics Names Gene Mack as CFO	08/04
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer	08/04
Gain Therapeutics, Inc. Appoints Gene Mack as Chief Financial Officer	08/04
Gain Therapeutics Names Chief Medical Officer	01/04
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer	01/04
Gain Therapeutics, Inc. Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer	01/04
Gain Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update	26/03
Gain Therapeutics to Present at Public Ventures Discovery Day	15/03
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease	05/03
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease	27/02
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease	27/02
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer	22/02
Gain Therapeutics, Inc. Appoints Gianluca Fuggetta as the Vice President of Finance and Principal Financial Officer from Senior Director, Finance & Corporate Reporting and Principal Accounting Officer, Effective March 1, 2024	22/02
Gain Therapeutics, Inc. Announces the Resignation of C. Evan Ballantyne as Chief Financial Officer, Effective March 1, 2024	22/02
Certain Common Stock of Gain Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-FEB-2024.	19/02
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight	14/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Gain Therapeutics, Inc.

Actions

GANX

US36269B1052

Autres langues

Filtres